IBR854

Phase 2Small molecule

IImbioray (Hangzhou) Biomedicine Co., Ltd.

IBR854 is one of 45 small molecule programs targeting Renal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CarcinomaActive, not recruiting

Renal Cell Carcinoma (RCC)Recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Renal Cell Carcinoma (RCC)Phase 2

Recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Votrient

Novartis

Phase 3

25 3

Nexavar

Bayer

Phase 3

23 4

Lenvima

Eisai

Phase 3

21 5

Inlyta

PPrism Pharmaceuticals

Phase 3

27 6

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

18 7

Imjudo

AstraZeneca

Phase 3

3 8

Depo-Provera

Eli Lilly

Phase 3

1 9

TKI258

Novartis

Phase 3

1 10

Roferon-a

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Renal Cell Carcinoma (RCC)

NCT07087158

Clinical

Trials by Indication[1]

Renal Cell Carcinoma (RCC)1 trial

A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Recruiting·IImbioray (Hangzhou) Biomedicine Co., Ltd.·Phase 2·NCT07087158·30 enrolled

Solid Tumor1 trial

A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR854 Cell Injection in Patients With Unresectable Locally Advanced Or Metastatic Solid Tumors

Completed·IImbioray (Hangzhou) Biomedicine Co., Ltd.·Phase 1·NCT06001684·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IBR854. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IBR854 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IBR854. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imbioray (Hangzhou) Biomedicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IImbioray (Hangzhou) Biomedicine Co., Ltd.

IBR854

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Renal Cell Carcinoma (RCC)1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News